Psoriasis is a chronic inflammatory skin disease that affects 2.2% of Americans and is a substantial detriment on the quality of life. Psoriasis is a complex interaction between numerous immune cells and has been considered largely a T-helper type 1 (Th1) T-cell-mediated response. Although numerous cytokines, including tumor necrosis factor-αβ, interleukin 1β, and interferon-γ, have been identified with distinct roles in skin inflammation and psoriasis, proinflammatory functions of newly identified cytokines have been linked recently to the alternative T-cell subsets Th17 and Th22 that are distinct in their functions and cytokine profiles. This review summarizes the basic research, translational applications, and new therapeutic developments contributing to the understanding of the diversity of human effector CD4+ Th1, Th17, and Th22 T cells, as well as the proinflammatory cytokines associated with these subsets in psoriasis.
PereraG.K., DiMeglioP., NestleF.O.Psoriasis. Annu Rev Pathol Mech Dis.2012; 7: 385–422.
2.
Guttman-YasskyE., NogralesK.E., KruegerJ.G.Contrasting pathogenesis of atopic dermatitis and psoriasis - Part I: Clinical and pathologic concepts. J Allergy Clin Immunol.2011; 127: 1110–8.
3.
Guttman-YasskyE., NogralesK.E., KruegerJ.G.Contrasting pathogenesis of atopic dermatitis and psoriasis - Part II. Immune cell subsets and therapeutic concepts. J Allergy Clin Immunol.2011; 127: 1420–32.
4.
AlamanosY., VoulgariP.V., DrososA.A.Incidence and prevalence of psoriatic arthritis: A systematic review. J Rheumatol.2008; 35: 1354–8.
5.
SchönM.P., BoehnckeW.H.Psoriasis. N Engl J Med2005; 352: 1899–1912.
6.
SternR.S., NijstenT., FeldmanS.R., MargolisD.J., RolstadT.Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction. J Investig Dermatol Symp Proc2004; 9: 136–9.
7.
KupperT.S., FuhlbriggeR.C.Immune surveillance in the skin: mechanisms and clinical consequences. Nat Rev Immunol.2004; 4: 211–22.
8.
GaspariA.A.Innate and adaptive immunity and the pathophysiology of psoriasis. J Am Acad Dermatol.2006; 54(3 suppl 2): s67–s80.
9.
JabbariA., Johnson-HuangL.M., KruegerJ.G.Role of the immune system and immunolgical circuits in psoriasis. G Ital Dermatol Venereol2011; 146: 17–30.
10.
SchonthalerH.B., Guinea-ViniegraJ., WagnerE.F.Targeting inflammation by modulating the Jun/AP-1 pathway. Ann Rheum Dis.2011; 70[Supplement 1]: i109–12.
11.
MortelM.R., EmerJ.Prospective new biologic therapies for psoriasis and psoriatic arthritis. J Drugs Dermatol.2010; 9: 947–58.
12.
LowesM.A., BowcockA.M., KruegerJ.G.Pathogenesis and therapy of psoriasis. Nature.2007; 445: 866–73.
13.
AlbanesiC., PastoreS.Pathobiology of chronic inflammatory diseases: interplay between keratinocytes and immune cells as a target for anti-inflammatory drugs. Curr Drug Metab.2010; 11: 210–27.
14.
NickoloffB.J., NestleF.O.Recent insights into the immunopathogenesis of psoriasis provide new therapeutic opportunities. J Clin Invest2004; 113: 1664–75.
NestleF.O., KaplanD.H., BarkerJ.Mechanisms of Disease. Psoriasis. N Engl J Med.2009; 361: 496–509.
17.
BarkerJ.N.The pathophysiology of psoriasis. Lancet.1991; 338: 227–30.
18.
Buske-KirschbaumA., KernS., EbrechtM., HellhammerD.H.Altered distribution of leukocyte subsets and cytokine production in response to acute psychosocial stress in patients with psoriasis vulgaris. Brain Behav Immun.2007; 21: 92–9.
19.
van BeelenA.J., TeunissenM.B.M., KapsenbergM.L.Interleukin-17 in inflammatory skin disorders. Curr Opin Allergy Clin Immunol.2007; 75: 374–81.
20.
LowesM.A., KikuchiT., Fuentes-DuculanJ.Psoriasis vulgaris lesions contain discrete populations of Th1 and Th17 T cells. J Invest Dermatol.2008; 128: 1207–11.
21.
LundyS.K., SarkarS., FoxD.A.Th17 cells in human disease. Immunol Revs.2008; 223: 87–113.
22.
SchotteliusA., MoldawerL.L., DinarelloC.A., AsadullahK., SteeryW., EdwardsC.K.IIIBiology of tumor necrosis factor-α (TNF-α): Implications for psoriasis. Exper Dermatol.2004; 13: 193–222.
23.
EdwardsC.K.III, MartinS.W., SeeleyA.J.Design of pegylated soluble tumor necrosis factor receptor type I (PEG sTNF-RI) for chronic inflammatory diseases. Site specific pegylation of polypeptides. Advan Drug Deliv Revs.2003; 55: 1315–36.
24.
GottliebA.B., MethesonR.T., LoweN., ZitnikR.Efficacy of Enbrel in patients with psoriasis. J Invest Dermatol.2002; 119: 234
HykaN., DayerJ.M., ModouxC., KohnoT., EdwardsCK3rd, Roux-LombardP.Apolipoprotein A-I inhibits the production of interleukin-1beta and tumor necrosis factor-alpha by blocking contact-mediated activation of monocytes by T lymphocytes. Blood2001; 97: 2381–89.
27.
EdwardsC.K.IIICombination cytokine therapy in rheumatoid arthritis The next generation. J Clin Rheumatol.2001; 7: S17–S24.
28.
MarrakchiS., GuigueP., RenshawB.R., PuelA., PeiX.Y., FraitagS.Interleukin-36-receptor antagonist deficiency and generalized pustular psoriasis. N Engl J Med.2011; 365: 620–27.
29.
JohnstonA., XingX., GuzmanA.M., RiblettM., LoydC.M., WardN.L.IL-1F5, -F6, -F8, and -F9: a novel IL-1 family signaling system that is active in psoriasis and promotes keratinocyte antimicroial peptide expression. J Immunol.2011; 186: 2613–22.
30.
LindroosJ., SvenssonL., NorsgaardH., LovatoP., MollerK., HagedornP.H.IL-23-mediated epidermal hyperplasia is dependent on IL-6J Invest Dermatol.2011; 131: 1110–8.
31.
GlowackaE., LewkowiczP., RotsztejnH., ZalewskaA.8, IL12, and L10 cytokines generation by neutrophils, fibroblasts and neutrophils-fibroblasts interaction in psoriasis. Adv Med Sci.2010; 55: 254–60.
32.
SabatR.IL-10 family of cytokines. Cytokine Growth Factor Rev2010; 21: 315–24.
33.
WolkK., KunzS., AsadullahK., SabatR.Cutting edge: Immune cells as sources and targets of the IL-10 family members?J Immunol5397–402
34.
GottliebA.B., LeonardiC., KerdelF., MehlisS., OldsM., WilliamsD.A.Efficacy and safety of briakinumab versus etanercept and placebo in patients with moderate to severe chronic plaque psoriasis. Br J Dermatol.2011; 165: 1–29.
35.
LuoJ., WuS.J., LacyE.R.Structural basis for the dual recognition of L-12 and IL-23 by ustekinumab. J Mole Biol.2010; 402: 797–812.
36.
KandaN., ShimizuT., TadaY., WatanabeS.IL-18 enhances IFN-gamma-induced production of CXCL9, CXCL10, and CXCL11 in human keratinocytes. Eur J Immunol.2007; 37: 338–50.
37.
BlumbergH., DinhH., DeanC.Jr., TruebloodE.S., BaileyK., ShowsD.L-1RL2 and its ligands contribute to the cytokine network in psoriasisJ Immunol.2011; 185: 4354–62.
38.
NakajimaH., NakajimaK., TarutaniM., MorishigeR., SanoS.Kinetics of circulating Th17 cytokines and adipokines in psoriasis patients. Arch Dermatol Res.2011; 303: 451–55.
39.
KagamiS., RizzoH.L., LeeJ.J., KoguchiY., BlauveltA.Circulating Th17, Th22, and Th1 cells are increased in psoriasis. J Invest Dermatol.2010; 130: 1373–83.
40.
RizzoH.L., KagamiS., PhillipsK.G., KurtzS.E., JacquesS.L., BlauveltA.IL-23-mediated psoriasis-like epidermal hyperplasia is dependent on IL17A. J Immunol.2011; 186: 1495–1502.
41.
AzumaY.T., NakajimaH., TakeuchiT.IL19 as a potential therapeutic in autoimmune and inflammatory diseases. J Pharmaol Sci.2011; 115: 105–11.
KingoK., MössnerR., RätsepR., RaudK., KrügerU., SilmH.Association analysis of IL20RA and IL20RB genes in psoriasis. Genes Immun.2008; 9: 445–51.
44.
SabatR., WolkK.Research in practice: IL-22 and IL-20: Significance for epithelial homeostasis and psoriasis pathogenesis. J Dtsch Dermatol Ges.2011; 9: 518–23.
WitteE., WitteK., WarszawskaK., SabatR., WolkK.Interleukin-22: A cytokine produced by T, NK, and NKT cell subsets, with importance in the innate immune defense and tissue production. Cytokine Growth Factor Reviews.2010; 21: 365–79.
47.
ZhangN., PanH.F., YeD.Q.Th22 in inflammatory and autoimmune disease: prospects for therapeutic intervention. Mol Cell Biochem.2011; 353: 41–6.
48.
OuyangW.Distinct roles of IL-22 in human psoriasis and inflammatory bowel disease. Cytokine Growth Factor Rev.2010; 21: 435–41.
49.
AggarwalS., GhilardiN., XieM.H., de SauvageF.J., GurneyA.L.Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17. J Biol Chem.2003; 278: 1910–14.
50.
TonelG., ConradC., LaggnerU., Di MeglioP., GrysK., McClanahanT.K.Cutting edge: A critical functional role for IL23 in psoriasis. J Immunol.2010; 185: 5688–91.
51.
LengR.X., PanH.F., TaoJ.H., YeD.Q.IL-19, IL-20, and IL-24: Potential therapeutic targets for autoimmune diseases. Expert Opin Ther Targets.2011; 15: 119–26.
52.
MargueC., KreisS.IL-24: physiological and supraphysiological effects on normal and malignant cells. Curr Med Chem.2010; 17: 3318–26.
53.
KopfM., BachmannM.F., MarslandB.J.Averting inflammation by targeting the cytokine environment. Nat Rev Drug Disc.2010; 9: 703–18.
54.
ChoJ.H., GregersenP.K.Genomics and the multifactorial nature of human autoimmune disease. N Engl J Med.2011; 365: 1612–23.
55.
BeutlerB., GreenwaldD., HulmesJ.D., ChangM., PanY.C., MathisonJ.Identity of tumour necrosis factor and the macrophage-secreted factor cachectin. Nature.1985; 316: 552–54.
LanzavecchiaA., SallustoF.Understanding the generation and function of memory Tcell subsets. Curr Opin Immunol.2005; 17: 326–32.
62.
SharpeA.H., AbbasA.K.T-cell costimulation-biology, therapeutic potential, and challenges. N Engl J Med.2006; 355: 973–75.
63.
McFarlandH.F.The B Cell - old player, new position on the team. N Engl J Med.2008; 358: 664–65.
64.
MosmannT.R., CherwinskiH., BondM.W., GiedlinM.A., CoffmanR.L.Two types of murine helper T cell clones. I. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol1986; 136: 2348–57.
65.
McInnesI.B., SchettG.Mechanisms of disease. The pathogenesis of rheumatoid arthritis. N Engl J Med.2011; 365: 2205–19.
66.
JägerA., KuchrooV.K.Effector and regulatory T-cell subsets in autoimmunity and tissue inflammation. Scand J Immunol2010; 72: 173–84.
67.
JacobS.E., NassiriM., KerdelF.A., VincekV.Simultaneous measurement of multiple Th1 and Th2 serum cytokines in psoriasis and correlation with disease severity. Mediators Inflamm.2003; 12: 309–13.
68.
LazarevicV., GlimcherL.H.T-bet in disease. Nat Immunol2011; 12: 597–606.
69.
KanoS., SatoK., MorishitaY., VollstedtS., KimS., BishopK.The contribution of transcription factor IRF1 to the interferon-g-interleukin 12 signaling axis and Th1 versus Th17 differentiation of CD4+ T cellsNat Immunol.2008; 9: 34–41.
70.
KawamuraT., OgawaY., ShimozatoO., AndoT., NakaoA., KobataT.CD70 is selectively expressed on Th1 but not Th2 cells and is required for Th1-type immune responses. J Invest Dermatol2011; 131: 1252–61.
71.
de KoningH.D., KamsteegM., Rodijk-OlthuisD., van Vlijmen-WillemsIM, van ErpP.E., SchalkwijkJ.Epidermal expression of host response genes upon skin barrier disruption in normal skin and uninvolved skin of psoriasis and atopic dermatitis patients. J Invest Dermatol2011; 131: 263–66.
72.
WisniewskiJ.A., BorishL.Novel cytokine and cytokine-producing T cells in allergic disorders. Allergy Asthma Proc.2011; 32: 83–94.
73.
WeiG., AbrahamB.J., YagiR., JothiR., CuiK., SharmaS.Genome-wide analyses of transcription factor GATA3-mediated gene regulation in distinct T cell types. Immunity.2011; 35: 299–311.
MosserD.M., EdwardsJ.P.Exploring the full spectrum of macrophage activation. Nat Rev Immunol.2008; 8: 958–69.
78.
Frausto-Del-RíoD., Soto-CruzI., Garay-CanalesC., AmbrizX., SoldevilaG., Carretero-OrtegaJ.Interferon gamma induces actin polymerization, Rac1 activation and down regulates phagocytosis in human monocytic cells. Cytokine.2012; 57: 158–68.
79.
OdegaardJ.I., ChawlaA.Alternative macrophage activation and metabolism. Annu Rev Pathol Mech Dis.2012; 6: 275–97.
80.
IvashkivL.B.Inflammatory signaling in macrophages: transitions from acute to tolerant and alternative activation states. Eur J Immunol2011; 41: 2477–81.
81.
NikolicB., LeeS., BronsonR.T., GrusbyM.J., SykesM.Th1 and Th2 mediate acute graft-versus-host disease, each with distinct end-organ targets. J Clin Invest.2000; 105: 1289–98.
82.
AgnelloD., LankfordC.S., BreamJ., MorinobuA., GadinaM., O'SheaJ.J.Cytokines and transcription factors that regulate T helper cell differentiation: new players and new insights. J Clin Immunol2003; 23: 147–61.
83.
MaldonadoR.A., SorianoM.A., PerdomoL.C., SigristK., IrvineD.J., DeckerT.Control of T helper cell differentiation through cytokine receptor inclusion in the immunological synapse. J Exp Med.2009; 206: 877–92.
84.
GutcherI., BecherB.APC-derived cytokines and T cell polarization in autoimmune inflammation. J Clin Invest.2007; 117: 1119–27.
85.
BoymanO., LétourneauS., KriegC., SprentJ.Homeostatic proliferation and survival of naive and memory T cells. Eur J Immunol2009; 39: 2088–94.
86.
ZhuJ., PaulW.E.Peripheral CD4 + T-cell differentiation regulated by networks and transcription factors. Immunol Rev.2010; 238: 247–62.
87.
SakaguchiS., SakaguchiN., AsanoM., ItohM., TodaM.Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor α-chains (CD25). J Immunol.1995; 155: 1151–64.
88.
GaoL., LiK., LiF., LiH., LiuL., WangL.Polymorphisms in the FOXP3 gene in Han Chinese psoriasis patients. J Dermatol Sci.2010; 57: 51–6.
KorethJ., MatsuokaK., KimH.T., McDonoughS.M., BindraB., AlyeaEP3rdInterleukin-2 and regulatory T cells in graft-versus-host diseaseN Engl J Med.2011; 365: 2055–66.
91.
KingC., TangyeS.G., MackayC.R.follicular helper (TFH) cells in normal and dysregulated immune responses. Annu Rev Immunol2008; 26: 741–66.
92.
VogelzangA., McGuireH.M., YuD., SprentJ., MackayC.R., KingC.A fundamental role for interleukin-21 in the generation of T follicular helper cells. Immunity.2008; 29: 127–37.
93.
DeenickE.K., MaC.S.The regulation and role of T follicular helper cells in immunity. Immunology.2011; 134: 361–67.
94.
CrottyS.Follicular helper CD4+ T cells (TFH). Annu Rev Immunol2011; 29: 621–63.
95.
LiX., MurrayF., KoideN., GoldstoneJ., DannS.M., ChenJ.Divergent requirement for Gas and cAMP in the differentiation and inflammatory profile of distinct mouse Th subsets. J Clin Invest2012; 122: 963–73.
96.
Acosta-RodriguezE.V., NapolitaniG., LanzavecchiaA., SallustoF.Interleukins 1 beta and 6 but not transforming growth factor-beta are essential for the differentiation of interleukin 17-producing human T helper cells. Nat Immunol.2007; 8: 942–9.
97.
KleinschekM.A., OwyangA.M., Joyce-ShaikhB., LangrishC.L., ChenY., GormanD.M.IL-25 regulates Th17 function in autoimmune inflammation. J Exp Med.2007; 204: 161–70.
98.
CosmiL., CimazR., MaggiL., SantarlasciV., CaponeM., BorrielloF.Evidence of the transient nature of the Th17 phenotype of CD4 + CD161+ T cells in the synovial fluid of patients with juvenile idiopathic arthritis. Arthritis Rheum.2011; 63: 2504–15.
99.
CosmiL., De PalmaR., SantarlasciV., MaggiL., CaponeM., FrosaliF.Human interleukin 17-producing cells originate from a CD161 +CD4 + T cell precursor. J Exp Med.2008; 205: 1903–16.
100.
YaoZ., PainterS.L., FanslowW.C., UlrichD., MacduffB.M., SpriggsM.K.Human IL-17: a novel cytokine derived from T cells. J Immunol1995; 155: 5483–86.
101.
TeunissenM.B., KoomenC.W., de Waal MalefytR., WierengaE.A., BosJ.D.Interleukin-17 and interferon-gamma synergize in the enhancement of proinflammatory cytokine production by human keratinocytes. J Invest Derm.1998; 111: 645–49.
102.
ShinH.C., BenbernouN., EsnaultS., GuenounouM.Expression of IL-17 in human memory CD45RO+ T lymphocytes and its regulation by protein kinase A pathway. Cytokine.1999; 11: 257–66.
103.
AarvakT., ChabaudM., MiossecP., NatvigJ.B.IL-7 is produced by some proinflammatory Th1/Th0 cells but not by Th2 cells. J Immunol1999; 162: 1246–51.
104.
AlbanesiC., CavaniA., GirolomoniG.IL-17 is produced by nickel-specific T lymphocytes and regulates ICAM-1 expression and chemokine production in human keratinocytes: synergistic or antagonist effects with IFN-gamma and TNF-alpha. J Immunol1999; 162: 494–502.
105.
HarringtonL.E., HattonR.D., ManganP.R., TurnerH., MurphyT.L., MurphyK.M.Interleukin 17-producing CD4+ effector T cells develop via lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol2005; 6: 1123–32.
106.
ParkH., LiZ., YangX.O., ChangS.H., NurievaR., WangY.H.A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol.2005; 6: 1133–41.
107.
WaismanA.T helper cell populations: As flexible as the skin. Eur J Immunol.2011; 41: 2539–43.
OuyangW., FilvaroffE., HuY., GroganJ.Novel therapeutic targets along the Th17 pathway. Eur J Immunol.2009; 39: 670–75.
110.
LeeW.W., KangS.W., ChoiJ., LeeS.H., ShahK.Regulating human Th17 cells via differential expression of IL-1 receptor. Blood2010; 115: 530–40.
111.
TokuraY., MoriT., HinoR.Psoriasis and other Th17-mediated diseasesJ UOEH.2010; 324: 317–28.
112.
HuhJ.R., LeungM.W., HuangP., RyanD.A., KroutM.R., MalapakaR.R.Digoxin and its derivatives suppress Th17 cell differentiation by antagonizing ROR-γt activity. Nature.2011; 472: 486–90.
113.
BovenschenH.J., van de KerkhofP.C., van ErpP.E., WoestenenkR., JoostenI., KoenenHJPMFoxp3+ regulatory T cells of psoriasis patients easily differentiate into IL17A-producing cells and are found in lesional skin. J Invest Dermatol.2011; 139: 1853–60.
114.
RachitskayaA.V., HansenA.M., HoraiR., LiZ., VillasmilR., LugerD.Cutting edge: NKT cells constitutively express IL-23 receptor and RORgammat and rapidly produce IL-17 upon receptor ligation in an IL-6-independent fashion. J Immunol.2008; 180: 5167–71.
CrellinN.K., TrifariS., KaplanC.D., Satoh-TakayamaN., Di SantoJ.P., SpitsH.Regulation of cytokine secretion in human CD127 + LTi-like innate lymphoid cells by toll-like receptor 2. Immunity.2010; 33: 752–64.
117.
ResP.C.M., PiskinG., de BoerO.J.Overrepresentation of IL-17A and IL-22 producing CD8 T cells in lesional skin suggests their involvement in the pathogenesis of psorasis. PLoS One.2010; 5: 1–11.
118.
LinA.M., RubinC.J., KhandpurR., WangJ.Y., RiblettM., YalavarthiS.Mast cells and neutrophils release IL-17 through extracellular trap formation in psoriasis. J Immunol.2011; 187: 490–500.
119.
MiossecP.Clinical implications of Th17/IL-17: Diseases that may benefit from manipulating the Th17 pathway. Eur J Immunol2009; 39: 667–9.
120.
WeaverC.T.Th17: The ascent of a new effector T cell subset. Eur J Immunol.2009; 39: 634–76.
121.
“Entrez Gene: IL17A interleukin 17A [Homo sapiens] Gene ID: 3605 updated on 26 Dec 2011. PubMed. 2012
122.
ReynoldsJ.M., AngkasekwinaiP., DongC.IL-17 family member cytokines: Regulation and function in innate immunity. Cytokine Growth Factor Rev.2010; 21: 413–23.
123.
ChangS.H., DongC.A novel heterodimerric cytokine consisting of IL-17 and IL-17F regulates inflammatory responses. Cell Res2007; 17: 435–40.
124.
WeaverC.T., HattonR.D., ManganP.R., HarringtonL.E.IL-17 family cytokine and the expanding diversity of effector T cell lineages. Annu Rev Immunol.2007; 25: 821–52.
125.
JohansenC., RiisJ.L., GedebjergA., KragballeK., IversenL.Tumor necrosis factor α-mediated induction of interleukin 17C in human keratinocytes is controlled by nuclear factor κβ. J Biol Chem2011; 286: 25487–94.
126.
KollsJ.K., LindénA.Interleukin-17 family members and inflammationImmunity.2004; 21: 467–76.
127.
ZhengY., DanilenkoD.M., ValdezP., KasmanI., Eastham-AndersonJ., WuJ.Interleukin-22, a T(H)17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis. Nature.2007; 445: 648–51.
128.
SchwandnerR., YamaguchiK., CaoZ.Requirement of tumor necrosis factor receptor-associated factor (TRAF)6 in interleukin 17 signal transduction. J Exp Med.2000; 191: 1233–40.
129.
JiangC.K., FlanaganS., OhtsukiM., ShuaiK., FreedbergI.M., BlumenbergM.Disease-activated transcription factor: allergic reactions in human skin cause nuclear translocation of STAT-91 and induce synthesis of keratin K17. Mol Cell Biol.1994; 14: 4759–69.
130.
FuM., WangG.Keratin 17 as a therapeutic target for the treatment of psoriasis. J Dermatol Sci.2012; 61: 161–5.
131.
Di CesareA., Di MeglioP., NestleF.O.The IL-23/Th17 axis in the immunopathogenesis of psoriasis. J Invest Dermatol2009; 129: 1339–50.
132.
IchiharaA., JinninM., OyamaR., YamaneK., FujisawaA., SakaiK.Increased serum levels of miR-1266 in patients with psoriasis vulgarisEur J Dermatol.2012; 22: 68–71.
133.
DongC.Diversification of T-helper-cell lineages: finding the family root of IL-17 producing cells. Nat Rev Immunol.2006; 6: 329–33.
McGeachyM.J., ChenY., TatoC.M., LaurenceA., Joyce-ShaikhB., BlumenscheinW.M.The interleukin 23 receptor is essential for the terminal differentiation of interleukin-17-producing effector T helper cells in vivo. Nat Immunol.2009; 10: 314–24.
136.
ChungY., ChungY., ChungY.Don't leave home without it: the IL23 visa to Th17 cells. Nat Immunol.2009; 103: 236–8.
137.
WiekowskiM.T., LeachM.W., EvansE.W., SullivanL., ChenS.C., VassilevaG.Ubiquitous transgenic expression of the IL-23 subunit p19 induces multiorgan inflammation, runting, infertility, and premature death. J Immunol.2001; 166: 7563–70.
138.
NakajimaK., KandaT., TakaishiM., ShigaT., MiyoshiK., NakajimaH.Distinct roles of IL23 and IL17 in the development of psoriasis-like lesions in a mouse model. J Immunol.2011; 186: 4481–9.
139.
LeeE., TrepicchioW.L., OestreicherJ.L., PittmanD., WangF., ChamianF.Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris. J Exp Med.2004; 199: 125–30.
140.
FitchE.L., RizzoH.L., KurtzS.E., WegmannK.W., GaoW., BensonJ.M.Inflammatory skin disease in K5.hTGF-β1 transgenic mice is not dependent on the IL23/Th17 inflammatory pathway. J Invest Derm2009; 129: 2443–50.
HabibT., SenadheeraS., WeinbergK., KaushanskyK.The common gamma chain (γc) is a required signaling component of the IL21 receptor and supports IL21-induce cell proliferation via JAK3Biochemistry.2002; 41: 8725–31.
143.
WeiL., LaurenceA., EliasK.M., O'SheaJ.J.IL-21 is produced by Th17 cells and drives IL-17 production in a Stat3-dependent manner. J Biol Chem2007; 282: 34605–10.
144.
SivakumarP.V., FosterD.C., CleggC.H.Interleukin-21 is a T-helper cytokine that regulates humoral immunity and cell-mediated anti-tumour responses. Immunology.2004; 112: 177–82.
145.
TerrierB., GeriG., ChaaraW., AllenbachY., RosenzwajgM., Costedoat-ChalumeauN.IL-21 modulates Th1 and Th17 responses in giant cell arteritis. Arthritis Rheum.2011; 64: 2001–11.
146.
WarrenR.B., SmithR.L., FlynnE., BowesJ., EyreS.A systematic investigation of confirmed autoimmune loci in early-onset psoriasis reveals an association with IL2/IL21. Brit J Derm.2011; 164: 660–4.
147.
DumoutierL., LouahedJ., RenauldJ.C.Cloning and characterization of L-10-related T cell-derived inducible factor (IL-TIF), a novel cytokine structurally related to IL-10 and inducible by IL-9. J Immunol2000; 164: 1814–9.
148.
DumoutierL., Van RoostE., AmeyeG., MichauxL., Renauld JC L-TIF/IL-22: genomic organization and mapping of the human and mouse genes. Genes Immun.2000; 1: 488–94.
149.
Entrez Gene. Entrez Gene: IL22 interleukin 22 [Homo sapiens] Gene ID 50616, updated on 4-Dec-2011. PubMed. 2012
150.
SestitoR., MadonnaS., ScarponiC., CianfaraniF., FaillaC.M., CavaniA.STAT3-dependent effects of IL22 in human keratinocytes are counterregulated by sirtuin 1 through a direct inhibition of STAT3 acetylation. FASEB J.2011; 25: 916–27.
151.
LiangS.C., TanX.Y., LuxenbergD.P., KarimR., Dunussi-JoannopoulosK., CollinsM.Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance expression of antimicrobial peptides. J Exp Med.2006; 203: 2271–9.
152.
YangX.O., PappuB.P., NurievaR., AkimzhanovA., KangH.S., ChungY., MaL.TH17 lineage differentiation is programmed by orphan nuclear receptors RORα and RORγ. Immunity.2008; 28: 29–9.
153.
AlamM.S., MaekawaY., KitamuraA., TanigakiK., YoshimotoT., KishiharaK.Notch signaling drives IL-22 secretion in CD4+ T cells by stimulating the aryl hydrocarbon receptor. Proc Natl Acad Sci USA2010; 107: 5943–8.
154.
WaismanA.T helper cell populations: As flexible as the skin?Eur J Immunol.2539–43
155.
TrifariS., KaplanC.D., TranE.H., CrellinN.K., SpitsH.Identification of a human helper T cell population that has abundant production of interleukin 22 and is distinct from Th17, Th1, and Th2 cells. Nat Immunol.2009; 10: 864–71.
156.
DuhenT., GeigerR., JarrossayD., LanzavecchiaA., SallustoF.Production of interleukin 22 but not interleukin 17 by a subset of human skin-homing memory T cells. Nat Immunol.2009; 10: 857–63.
157.
EyerichS., EyerichK., CavaniA., Schmidt-WeberC.IL-17 and IL-22: siblings, not twins. Trends Immunol.2010; 31: 354–61.
158.
ZenewiczL.A., FlavellR.A.Recent advances in IL22 biology. Int Immunol2011; 23: 159–63.
159.
SonnenbergG.F., FouserL.A., ArtisD.Border patrol: regulation of immunity, inflammation and tissue homeostasis at barrier surfaces by L22. Nat Immunol.2011; 12: 383–90.
160.
BabaN., RubioM., KeninsL., RegairazC., WoisetschlagerM., CarballidoJ.M.The aryl hydrocarbon receptor (AhR) ligand VAF347 selectively acts on monocytes and naïve CD4(+) Th cells to promote the development of IL-22-secreting Th cells. Hum Immunol2012; 73: 795–800.
161.
AkdisM., PalomaresO., van de VeenW.Th17 and Th22 cells: a confusion of antimicrobial response with tissue inflammation versus protection. Allergy Clin Immunol.2012; 129: 1438–49.
162.
SanjabiS., ZenewiczL.A., KamanakaM., FlavellR.A.Anti-inflammatory and pro-inflammatory roles of TGFβ, IL10, and IL22 in immunity and autoimmunity. Curr Opin Pharm.2009; 9: 447–53.
163.
MaH.L., LiangS., LiJ., NapierataL., BrownT., BenoitS.IL-22 is required for Th17 cell-mediated pathology in a mouse model of psoriasis-like skin inflammation. J Clin Invest.2008; 118: 597–607.
164.
WangX., FujitaM., PradoR., ToussonA., HsuH.C., SchotteliusA.Visualizing CD4T-cell migration into inflamed skin and its inhibition by CCR4/CCR10 blockades using in vivo imaging model. Brit J Derm2010; 162: 487–96.
165.
Van BelleA.B., de HeuschM., LemaireM.M., HendrickxE., WarnierG., Dunussi-JoannopoulosK.IL22 is required for imiquimod-induced psoriasiform skin inflammation in mice. J Immunol.2011; 188: 462–9.
166.
KotenkoS.V., IzotovaL.S., MirochnitchenkoO.V., EsterovaE., DickensheetsH., DonnellyR.P.Identification, cloning, and characterization of a novel soluble receptor that binds IL22 and neutralizes its activity. J Immunol.2001; 166: 7096–103.
167.
DumoutierL., LejeuneD., ColauD., RenauldJ.C.Cloning and Characterization of IL-22 Binding Protein, a Natural Antagonist of L-10-Related T Cell-Derived Inducible Factor/IL-22. J Immunol2001; 166: 7090–5
168.
TrifariS., SpitsH.IL-22-producing CD4+ T cells: Middle-men between the immune sytem and its environment. Eur J Immunol2010; 40: 2369–71.
EyerichS., EyerichK., PenninoD., CarboneT., NasorriF., PallottaS.Th22 cells represent a distinct human T cell subset involved in epidermal immunity and remodeling. J Clin Invest2009; 119: 3573–85.
171.
SzegediK., KremerA.E., KezicS., TeunissenM.B., BosJ.D., LuitenR.M.Increased frequencies of IL31-producing T cells are found in chronic atopic dermatitis skin. Exp Dermatol.2012; 21: 431–36.
172.
ZhangL., LiY-G, LiY-HIncreased frequencies of Th22 cells as well as Th17 cells in the peripheral blood of patients with ankylosing spondylitis and rheumatoid arthritis. PLoS One.2012; 7: 1–9.
173.
HuL-J, FrancisS.O., LiL.Autoreactive CLA Ag+ CD4+ CD45RO+ CCR4+ CCR6+CCR10+ Th22 memory T cells activate keratinocytes to produce the proinflammatory cytokine IL32γ in a cell-cell contact manner. J Clin Invest.2012; 121 [Communicated]
174.
KimS.H., HanS.Y., AzamT., YoonD.Y., DinarelloC.A.Interleukin-32: a cytokine and inducer of TNF alpha. Immunity.2005; 22: 131–42.
175.
SchaferJ.A., KjesboN.K., GleasonP.P.Formulary review of 2 new biologic agents: tocilizumab for rheumatoid arthritis and ustekinumab for plaque psoriasis. J Manag Care Pharm.2010; 16: 402–16.
176.
YeildingN., SzaparyP., BrodmerkelC., BensonJ., PlotnickM., ZhouH.Development of the IL-12/23 antagonist ustekinumab in psoriasis past present, and future perspectives. Ann NY Acad Sci2011; 1222: 30–9.
177.
BensonJ.M., SachsC.W., TreacyG.Therapeutic targeting of the IL-12/23 pathways: generation and characterization of ustekinumabNat Biotech.2011; 29: 615–24.
178.
LawsP.M., WarrenR.B.Ustekinumab for the treatment of psoriasis. Exp Rev Clin Immunol.2011; 7: 155–64.
179.
BensonJ.M., PerittD., ScallonB.J., HeavnerG.A., ShealyD.J., Giles-KomarJ.M.Discovery and mechanism of ustekinumab: A human monoclonal antibody targeting Interleukin-12 and Interleukin-23 for treatment of immune-mediated disorders. MAbs.2011; 3: 535–45.
180.
KurzejaM., RudnickaL., OlszewskaM.New interleukin-23 pathway inhibitors in dermatology: ustekinumab, briakinumab, and secukinumab. Am J Clin Dermatol.2011; 12: 113–25.
PappK.A., LeonardiC., MenterA., ThompsonE.H.Z., BaumgartnerS.Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis. N Engl J Med.366: 1181–9
183.
WaismanA.To be 17 again - anti-interleukin-17 treatment for psoriasis. N Engl J Med.2012; 366: 1251–2.
184.
EdwardsC.K.III, EisenmesserE.Z., NorrisD.A.Conducting drug discovery at the interface between innate and adaptive immunity. Cell Mol Immunol.2012; 8: 109. (Abstract)
185.
EdwardsC.K.IIIDrug discovery and development for inflammatory diseases. Exp Opin Ther Targets.2004; 8: 151–63.
